AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Dopamine Agonists

Summary

Researchers at Purdue University have developed new molecules that fully and selectively activate the dopamine D1 receptor. The compounds derived are useful for treating patients having a dopamine-related dysfunction of the central nervous system (CNS) as well as conditions in which peripheral dopamine receptors are involved. They are expected to be effective against Parkinson's disease, improving cognition, memory, attention deficit hyperactivity disorder, and related developmental disorders.

Technology Benefits

Lead compound is 50 times more selective for D1 receptors than for D2L receptorsEquipotent, but more selective than other D1 agonists Potentially effective treatment for advanced Parkinson's disease and other CNS disordersOrally bioavailable in animal models

Technology Application

Medical/HealthcarePharmaceuticalsDrug Development

Detailed Technology Description

David NicholsPurdue Medicinal Chemistry and Molecular Pharmacology

Countries

United States

Application No.

8,318,938

Country/Region

USA

For more information, please click Here